Clinical Trials
101 trialsMK-4280A-007
Merck Sharp & Dohme LLC
CodeBreak300
Amgen
EREMISS
Centre Oscar Lambret
REGO-SARC
Centre Oscar Lambret
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
DREAM
First Affiliated Hospital, Sun Yat-Sen University
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
MK-7902-017
Merck Sharp & Dohme LLC
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
REGOMA-2
Istituto Oncologico Veneto IRCCS
Study of Regorafenib in Patients With Advanced Myeloid Malignancies
Massachusetts General Hospital
CheckMate 9N9
Bristol-Myers Squibb
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Merck Sharp & Dohme LLC
ARC-9
Arcus Biosciences, Inc.
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
RePERSO
Rennes University Hospital
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Case Comprehensive Cancer Center
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
a-MANTRA
Gruppo Oncologico Italiano di Ricerca Clinica
REGONIVO
National Cancer Center Hospital East
REPROGRAM-01
Centre Hospitalier Universitaire de Besancon
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
Bayer
ROCKET
EpicentRx, Inc.
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Asan Medical Center
Regorafenib in Metastatic Colorectal Cancer
University of Rochester
GOING
Fundacion Clinic per a la Recerca Biomédica
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
SCRI Development Innovations, LLC
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Sumitomo Pharma America, Inc.
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Sarcoma Alliance for Research through Collaboration
REGOVAR
ARCAGY/ GINECO GROUP
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Stanford University
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Bayer
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Bayer
REGISTRI
Grupo Espanol de Investigacion en Sarcomas
RENOBATE
Asan Medical Center
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
RESOUND
Istituto Clinico Humanitas
REGOMA
Istituto Oncologico Veneto IRCCS
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
National Cancer Centre, Singapore
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
CStone Pharmaceuticals